Qualyst’s mission is to develop and deliver novel and proprietary ADMET technologies to the life sciences industry that increase the efficiency and effectiveness of drug discovery and development. Current product families include B-CLEAR® , an in vitro sandwich-cultured hepatocyte system for assessment of hepatobiliary disposition and drug transport, ACCURATE™, a high-throughput screen for CYP450-mediated metabolic activity, and ACCUPRO™ a high-throughput screen protein binding.